The long-awaited roll out of the enhanced drug Marketing Authorization Holder (MAH) program in China

Lei Liu

VP of Regulatory Affairs of FMD

As a part of the drug evaluation and approval reform in China, the enhanced Marketing Authorization
Holder (MAH) system is now law in China nation-wide. This law eliminates a significant hurdle for drug
developers in registering and marketing an innovative drug in China.